William Blair Investment Management LLC Sells 1,586,410 Shares of Certara, Inc. (NASDAQ:CERT)

William Blair Investment Management LLC trimmed its stake in Certara, Inc. (NASDAQ:CERT - Free Report) by 99.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,827 shares of the company's stock after selling 1,586,410 shares during the period. William Blair Investment Management LLC's holdings in Certara were worth $147,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of CERT. Atria Investments Inc raised its stake in Certara by 21.6% during the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company's stock worth $231,000 after acquiring an additional 3,501 shares during the period. KBC Group NV increased its stake in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after purchasing an additional 1,584 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Certara during the 3rd quarter valued at $367,000. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Certara in the 3rd quarter worth $1,513,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in Certara in the 3rd quarter worth $852,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Price Performance

NASDAQ CERT traded up $0.05 during trading on Monday, hitting $10.78. 936,649 shares of the stock traded hands, compared to its average volume of 1,012,203. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 12-month low of $9.41 and a 12-month high of $19.18. The firm has a 50-day simple moving average of $12.55 and a 200-day simple moving average of $11.49. The company has a market capitalization of $1.74 billion, a P/E ratio of -53.90, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60.

Remove Ads

Wall Street Analysts Forecast Growth

CERT has been the topic of several research analyst reports. Barclays boosted their price objective on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a research report on Friday, February 28th. William Blair reissued a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Stephens restated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Finally, TD Cowen assumed coverage on shares of Certara in a report on Thursday, February 27th. They issued a "buy" rating and a $16.00 target price on the stock. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Certara currently has an average rating of "Moderate Buy" and a consensus price target of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.